Skip to main content
Imran Khan, MD, Internal Medicine, New Brunswick, NJ

Imran Khan MD

Internal Medicine•New Brunswick, NJ

Hospital Medicine/Hospitalist, Hematology/Oncology

Physician

Join to view full profile

  • 125 Paterson StSte 5200New Brunswick, NJ 08901

  • Phone+1 732-235-6531

  • Fax+1 732-235-6797

Dr. Khan is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Khan's full profileAlready have an account?

Education & Training

  • Rutgers Health/Robert Wood Johnson Medical School
    Rutgers Health/Robert Wood Johnson Medical SchoolFellowship, Hematology and Medical Oncology, 2009 - 2012
  • Zucker School of Medicine at Hofstra/Northwell
    Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 2007 - 2009
  • Mass General Brigham/Brigham and Women's Hospital/Harvard Medical School
    Mass General Brigham/Brigham and Women's Hospital/Harvard Medical SchoolResidency, Radiology-Diagnostic, 2005 - 2007
  • Zucker School of Medicine at Hofstra/Northwell
    Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 2004 - 2005
  • Rutgers New Jersey Medical School
    Rutgers New Jersey Medical SchoolClass of 2004

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2009 - 2027

Publications & Presentations

PubMed

Press Mentions

  • ASH: J&J Makes Case for Tecvayli Combo as an Alternative to CAR-T in 2nd-Line Multiple Myeloma
    ASH: J&J Makes Case for Tecvayli Combo as an Alternative to CAR-T in 2nd-Line Multiple MyelomaDecember 9th, 2025
  • Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
    Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second LineMarch 14th, 2026

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Imran Khan, Dr. Imran Khan, MD, Dr. I Khan